Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHORE
2023-506558-20-00Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of amlitelimab in atopic dermatitis (AD) (3 arms), sponsored by Sanofi. Primary endpoints: Proportion of participants with vIGA-AD 0 or 1 and ≥2-point reduction from baseline at Week 24 (EU, EU reference countries, Japan), Proportion of participants achieving EASI-75 at Week 24 (EU, EU reference countries, Japan) and 1 more. Started Jun 2024; status: completed.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2023-506558-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506558-20-00.